Insurance Limits on GLP-1 Obesity Drugs Remain Despite Value Findings

GLP-1 medications—including Ozempic, Wegovy and Zepbound—have been judged cost-effective by the Institute for Clinical and Economic Review (ICER). Nevertheless, many U.S. insurance plans continue to limit access, often capping treatment at six months to one year. The restriction creates a gap between the drugs’ societal value and the budgetary impact on insurers.

Science Daily

The Centers for Disease Control and Prevention estimate that roughly 40 % of Americans are obese. Even a modest uptake of GLP-1 therapy could push insurer spending into the billions, far exceeding ICER’s budget-impact threshold of $821 million for the current year. Researchers at the University of Mississippi note that while the drugs deliver “tremendous value to society,” the sheer size of the eligible population generates a massive budget impact. Moreover, long-term cost savings remain unproven; existing data do not yet show reductions in cardiovascular, liver or kidney expenses that early treatment might promise. Patient adherence is also a challenge—many discontinue within the first year, and weight regain is common after stopping the medication. Sustained financial benefit for insurers would likely require coverage beyond the typical short-term limits and the provision of lifestyle-support services that were integral to clinical trial protocols.

Science Daily

When insurance does not cover brand-name GLP-1 drugs, some patients turn to cheaper compounded versions. Liang-Yuan Lin, a doctoral candidate in pharmacy administration, warns that these products are not subject to the rigorous review required of FDA-approved medications. The FDA has issued warning letters to compounded pharmacies for selling unapproved or incorrect ingredients, raising safety concerns about contamination, potency and proper handling. Lin advises patients to obtain GLP-1 therapy only under physician supervision to manage side effects and ensure the medication’s authenticity.

Science Daily

ICER’s analysis confirms the clinical benefits of GLP-1 drugs but flags the budget impact as a separate concern. The FDA’s warnings underscore regulatory scrutiny of non-approved compounded products. Sujith Ramachandran, associate professor of pharmacy administration, emphasizes that broader coverage could help patients maintain weight loss and reduce obesity-related disease risk, but he cautions that insurers must weigh the immediate fiscal burden against uncertain future savings.

Science Daily

“I, and I think most people, would hope that everybody who needs this medication gets it,” — Sujith Ramachandran, associate professor of pharmacy administration

Science Daily